Eli Lilly (LLY) and AbbVie (ABBV) topped a Credit Suisse evaluation of pharmaceutical companies heading into 2017, leaving more challenged Pfizer (PFE), AstraZeneca (AZN) and Novo Nordisk (NVO) in the dust.
But the PharmaValues 2017 list did little for IBD’s 44-company Medical-Ethical Drugs industry group, which fell a fraction on the stock market today, a fifth consecutive down day. The group is down more than 20% this year, touched a three-month low Monday and is trading below its 50-day moving average.
